Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

The Effect of Foot Massage With a Massage Roller on Chemotherapy-Related Neuropathic Pain

28. august 2026 opdateret af: Yasemin Ciraci Yasar, Ataturk University
Chemotherapy-related neuropathic pain is experienced by 30-40% of cancer patients. This pain significantly reduces the quality of life and overall well-being of patients battling cancer. Studies widely acknowledge that standardizing neuropathic pain assessment leads to improved patient outcomes. Our project, which we believe will add a different dimension to nursing care for cancer patients, aims to reduce chemotherapy-related neuropathic pain experienced by cancer patients through foot massage. The study population will consist of male and female cancer patients with chemotherapy-related neuropathic pain (VAS ≥ 4/10), over 18 years of age, who are actively undergoing treatment at the Medical Oncology Clinics of Atatürk University Research Hospital between February 1, 2026 and June 30, 2026, and who are not scheduled for surgical procedures during the research period. Accordingly, the minimum number of participants required for the study has been determined as 52. To reduce the risk of possible losses, withdrawals, or missing data during the research process, it is planned to include more participants than the calculated sample size. Within the scope of the research, the Neuropathic Pain Scale (S-LANSS) will be used to determine the presence of neuropathic pain in patients, and the VAS will be used to determine the severity of the pain. After the pre-test is completed, the control group will continue with routine treatment and care in the clinic. The intervention group will receive routine treatment and care, as well as foot massage using a foot massage roller for a total of 30 minutes twice a day. This intervention in the intervention group is planned to continue for 3 weeks. During this period, no other treatment will be applied to patients for neuropathic pain. The fact that only 3 small-scale studies, including one case report, were found in the literature review on this subject, the multidisciplinary collaboration in planning this study, and the expectation that it will offer practical solutions for chemotherapy-related neuropathic pain highlight the originality of the study. It is expected that the results obtained will provide evidence-based contributions to nursing care, support holistic approaches to improving patient comfort, and develop a viable intervention model for healthcare professionals.

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

80

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Erzurum
      • Erzurum, Erzurum, Tyrkiet (Türkiye), 25080
        • Atatürk Üniversitesi

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Beskrivelse

Inclusion Criteria:

(1) age ≥18, (2) receiving neurotoxic chemotherapy regimens including Taxanes (Paclitaxel/Docetaxel), Platinum (Carboplatin/Cisplatin), or a combination of both, (3) Having completed at least three cycles of chemotherapy, (4) scoring ≥ 12 on the S-LANSS scale, and ≥ 4 on the VAS, (5) being conscious, cooperative, and able to communicate in Turkish (6) volunteering to participate and providing written informed consent.

Exclusion Criteria:

(1) peripheral neuropathy pre-dating the chemotherapy (e.g., diabetic, alcoholic, or nutritional neuropathy) (2) receiving non-taxane/non-platinum regimens or Oxaliplatin-based chemotherapy, (3) active skin infections, open wounds, or severe scar tissue on the feet, (4) history of deep vein thrombosis or active bone/spine metastases in the lower extremities, (5) comorbidities affecting the sensory function of the nervous system.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Støttende pleje
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Enkelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: wooden massage roller
intervention group
Aktiv komparator: ıce therapy
control group

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Visual Analog Scale- Pain score
Tidsramme: 3 weeks
The Visual Analogue Scale (VAS), developed by Price et al. (1983), was utilized to assess and monitor pain intensity; it is a simple, repeatable, and widely used subjective method for rapid pain assessment [24]. In this method, participants marke their perceived pain on a 10 cm ruler, where 0 represent "no pain", and 10 represent 'the most severe or imaginable pain". In this study, pain intensity was categorized as 4 for "mild pain", 5-6 for "moderate pain", and 7-10 for "severe pain".
3 weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

1. februar 2026

Primær færdiggørelse (Faktiske)

30. juni 2026

Studieafslutning (Faktiske)

30. juli 2026

Datoer for studieregistrering

Først indsendt

11. juni 2026

Først indsendt, der opfyldte QC-kriterier

11. juni 2026

Først opslået (Faktiske)

16. juni 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

1. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

28. august 2026

Sidst verificeret

1. juni 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner